More specifically, Bhagavathula and colleagues pooled efficacy outcome data in the same analysis irrespective of type of comparator (placebo or GLP-1 RA) [26]
The study showed that, although not at statistical significance, there was a trend for a lower incidence of bronchitis, pneumonia, upper respiratory lung infection, lung squamous cell carcinoma, acute respiratory failure, asthma, chronic obstructive lung disease (COPD), pulmonary fibrosis, and lung oedema
Recommended for you L Carnitina Refuerza tus niveles de energa de forma natural con este aminocido
Phase I study of trastuzumab-DM1, an HER2 antibodydrug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer